Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy
- 1 December 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (12) , 3846-3853
- https://doi.org/10.1182/blood-2005-05-2034
Abstract
The interleukin-12 receptor β2 (Il12rb2) gene is silenced in tumor cells from different human B-cell malignancies as opposed to their normal counterparts. It was hypothesized that this silencing allows neoplastic B cells to escape the control exerted by IL-12 on their growth. The aim of this study was to investigate whether targeted inactivation of the Il12rb2 gene in mice resulted into increased susceptibility to spontaneous tumor formation and immunopathology. Il12rb2 gene–deficient animals developed in the first year of life immune-complex mesangial glomerulonephritis with serum antinuclear antibodies. In older animals, multiorgan lymphoid infiltrates with features of vasculitis and Sjögren syndrome were detected in association with systemic B- and T-cell activation. In half of aged animals, lymph node plasmacytoma or lung carcinoma was observed. A mechanism for spontaneous development of autoimmune pathology and B-cell tumors is suggested by a strong IL-6 up-regulation detected in splenocytes and lymphoid infiltrates associated with oligoclonal B-cell expansion. The emergence of lung tumors may likely be attributed to an interferon-γ (IFN-γ) deficiency secondary to lack of IL-12 signaling. The development of autoimmunity, lymphoproliferation, and B-cell tumors in Il12rb2 knockout (KO) mice suggests that IL-12 functions physiologically to restrain aberrant B-cell activation.Keywords
This publication has 24 references indexed in Scilit:
- The IL-12 Family of Heterodimeric Cytokines: New Players in the Regulation of T Cell ResponsesPublished by Elsevier ,2003
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Interleukin-12 in anti-tumor immunity and immunotherapyCytokine & Growth Factor Reviews, 2002
- Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic MiceThe Journal of Experimental Medicine, 2001
- The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose DependentThe Journal of Immunology, 2000
- A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunitsProceedings of the National Academy of Sciences, 1996
- IL‐12‐Deficient Mice Are Defective but Not Devoid of Type 1 Cytokine ResponsesAnnals of the New York Academy of Sciences, 1996
- Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones.The Journal of Experimental Medicine, 1994
- Antitumor and antimetastatic activity of interleukin 12 against murine tumors.The Journal of Experimental Medicine, 1993
- Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.Proceedings of the National Academy of Sciences, 1990